AstraZeneca, Pharma Strategy, Open Innovation, M&A / Mergers and Acquisitions, Corporate Venture Capital (CVC), Oncology, Cardiometabolic Disease

AstraZeneca, Pharma Strategy, Open Innovation, M&A / Mergers and Acquisitions, Corporate Venture Capital (CVC), Oncology, Cardiometabolic Disease

Will AstraZeneca's open innovation engine turn it into the next most valuable pharma company?

AstraZeneca's Open Innovation doctrine has already delivered a big chunk of its 16 Blockbusters and there are many assets lined up to become the next big ones. Jump in to see if the money is going where it should.